Peter Lebowitz, Third Arc Bio CEO
July 23, 2024 07:00 AM EDTUpdated August 20, 10:19 AM
Financing
Startups

At Third Arc Bio, for­mer J&J lead­ers raise $165M to test on­col­o­gy, au­toim­mune bi­o­log­ics

Kyle LaHucik

Senior Reporter

Af­ter more than a decade steer­ing John­son & John­son’s on­col­o­gy drug R&D, Pe­ter Lebowitz is ready for his next chal­lenge: shep­herd­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times